[Abdominoperineal amputation and radical lymphadenectomy (mesenteropelvic) in the treatment of cancer of the lower rectum. Anatomosurgery].

J Chir (Paris)

Division de Chirurgie Générale, Hôpital de Montefiascone USL VT/I, Viterbo, Italia.

Published: December 1989

The authors describe their anatomical study upon the use of the total pelvic lymphadenectomy in addition to the classic abdominoperineal amputation following Miles in the treatment of lower rectal cancer. They used a modification of the "cellulectomie pelvienne" de Brunschwig et Huguier applying to the rectum the procedure originally born for the surgery of uterine cancer. They underline the bad results of the conventional surgery in terms of survival and local recurrence due to the incomplete lymphatic resection. In front of the biology of the rectal cancer, which is a neoplasm with prevalent local malignity and high lymphotropism, this technique, which removes almost all the lymphnodes of the pelvis, can really improve the results of this surgery.

Download full-text PDF

Source

Publication Analysis

Top Keywords

rectal cancer
8
[abdominoperineal amputation
4
amputation radical
4
radical lymphadenectomy
4
lymphadenectomy mesenteropelvic
4
mesenteropelvic treatment
4
cancer
4
treatment cancer
4
cancer lower
4
lower rectum
4

Similar Publications

Background: Patients with rectal cancer (RC) are at risk of developing cancer-related cachexia, a complex metabolic syndrome that can negatively impact quality of life (QoL), treatment tolerance, and clinical response.

Objectives: The aim of the study was to explore the possible associations of the novel European Organization for Research and Treatment of Cancer QoL Questionnaire-Cancer Cachexia (EORTC QLQ-CAX24) scores with body composition parameters and physical performance in patients with locally advanced RC (LARC).

Methods: This prospective observational study involved RC patients evaluated at the dedicated outpatient clinic of Clinical Nutrition at the Fondazione Policlinico Agostino Gemelli IRCCS.

View Article and Find Full Text PDF

There is no reliable immune scoring system that can help us predict the postoperative outcomes of colorectal cancer patients with peritoneal metastases after cytoreductive surgery. In this cohort, the aims were (1) to evaluate the postoperative morbidity, mortality and surgical oncological outcomes in colorectal cancer patients with peritoneal metastasis; (2) to compare oncological and postoperative outcomes of colon cancer patients with peritoneal metastasis and rectal cancer patients with peritoneal metastasis; and (3) to assess the prognostic value of the modified Glasgow Prognostic Score (mGPS) and the CRP-albumin ratio (CAR). : A prospectively maintained database of 258 patients who underwent cytoreductive surgery for peritoneal metastases of colorectal origin between 2007 and 2024 was analyzed.

View Article and Find Full Text PDF

Colorectal Cancer: A Brief and Simplified Analysis of a Complex Disease.

Medicina (Kaunas)

December 2024

Department of Medical Genetics, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria.

This study examined factors influencing the onset and progression of colorectal tumors, including patients' epidemiological data, tumor location (right-sided, left-sided, and rectal), histomorphology, perineural or intraneural invasion, lymph node status, immune reactions, mismatch repair (MMR) status, and commonly observed mutations. Our primary goal was to evaluate their predictive and prognostic value and interactions. We analyzed a retrospective cohort of 100 patients with colorectal adenocarcinoma diagnosed between 2020 and 2023, using formalin-fixed paraffin-embedded (FFPE) tumor blocks.

View Article and Find Full Text PDF

: Colorectal cancer (CRC) ranks as the third most prevalent cancer globally and is the third leading cause of cancer-related deaths. In 2020 alone, there were over 1.9 million new cases of CRC and nearly 0.

View Article and Find Full Text PDF

Primary Prostatic Stromal Sarcoma: A Case Report and Review of the Literature.

Medicina (Kaunas)

November 2024

Division of Medical Oncology, Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara 06620, Türkiye.

: Primary prostatic stromal sarcoma is an exceptionally rare urological malignancy, constituting less than 0.1% of all prostatic cancers. It poses a significant clinical challenge due to its aggressive behavior and poor prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!